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Background: Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary
objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD)
and recommended phase II dose (RP2D). Secondary objectives included characterisation of the safety profile, pharmacokinetics
(PKs) and pharmacodynamics (PDs).
Methods: Heat-shock protein 990 was administered orally once or two times weekly on a 28-day cycle schedule in patients with
advanced solid tumours. Dose escalation was guided by a Bayesian logistic regression model with overdose control.
Results: A total of 64 patients were enrolled. Fifty-three patients received HSP990 once weekly at 2.5, 5, 10, 20, 30, 50 or 60mg,
whereas 11 patients received HSP990 two times weekly at 25mg. Median duration of exposure was 8 weeks (range 1–116 weeks)
and 12 patients remained on treatment for416 weeks. Dose-limiting toxicities occurred in seven patients and included diarrhoea,
QTc prolongation, ALT/AST elevations and central neurological toxicities. The most common drug-related adverse events were
diarrhoea, fatigue and decreased appetite. Further dose escalation beyond 60mg once weekly was not possible owing to
neurological toxicity. Rapid absorption, no drug accumulation and large interpatient variability in PK exposures were observed.
No objective responses were seen; 25 patients had a best overall response of stable disease.
Conclusions: Heat-shock protein 990 is relatively well tolerated, with neurological toxicity being the most relevant DLT. The single
agent MTD/RP2D of HSP990 was declared at 50mg once weekly.
Heat-shock proteins (HSPs) are molecular chaperones present in
almost every cellular compartment, stimulated by environmental
stress conditions such as infection, inflammation, starvation,
hypoxia and cancer (Macario and Conway de Macario, 2005).
Through correct protein folding and functional conformation,
HSPs protect cells from stress damage, leading to protein stability
(Macario and Conway de Macario, 2005). They are classified based
on their molecular weight into high-molecular-weight HSPs
(X100 kDa), in contrast to small HSPs (o34 kDa), as well as
those that fall in between these two categories with molecular
weights between 99 and 35 kDa (Macario and Conway de Macario,
2005). Within HSPs, HSP90 and HSP70 are two functionally
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related ATP-dependent chaperones that, despite their cooperation
to prevent protein aggregation through heat-shock factor 1, are
inversely regulated (i.e. HPS90 inhibits the expression of HSP70),
leading to feedback loop that limits the response to stress
(Erlichman, 2009). Overexpression of HSPs, in particular HSP90,
with consequent oncogenic protein stabilisation, stimulation of cell
proliferation, survival and angiogenesis has been shown to occur
commonly in cancer cells (Whitesell and Lindquist, 2005; Powers
and Workman, 2007; Neckers and Workman, 2012). For instance,
HSP90 is known to stabilise several growth factor receptors and
signal-transduction pathway regulators such as the epidermal
growth factor receptor (EGFR) (Shimamura et al, 2005). In
clinicopathological studies, tumour progression and poor prog-
nosis are associated with HSP overexpression in several cancer
types (Li et al, 2008; Simpson et al, 2010). Therefore, HSPs are an
attractive cancer target and their inhibitors have been developed in
preclinical and clinical settings.
Heat-shock protein 90 inhibitors demonstrate antitumour activity
in multiple tumour types both as single agents and in combination
with targeted therapies, standard chemotherapy or radiotherapy in
preclinical models (Sawai et al, 2008; Kim et al, 2009; Menezes et al,
2012). In addition, their role in HER-2-positive breast cancer alone
or in combination with anti-HER2 and hormonal therapy has been
described previously (De Mattos-Arruda and Cortes, 2012; Scaltriti
et al, 2012). An additional area of interest has been lung cancer. In
lung cancer cell lines, radioresistance can be induced through
hypoxia-inducible factor-1 (HIF-1) upregulation, enhanced HSP90–
HIF-1 interaction and PI3K/Akt/mTOR pathway activation. This
process can be reversed by the natural HSP90 inhibitor deregulin
(Kim et al, 2009). Recent studies have described potent in vitro and
in vivo ability of HSP90 inhibition in restoring drug responsiveness
in crizotinib-resistant anaplastic lymphoma kinase (ALK)-driven
non-small-cell lung cancer (NSCLC) models, via the loss of
echinoderm microtubule-associated protein-like 4 (ELM4)-ALK
fusion gene expression and oncogenic protein depletion (Chen
et al, 2013; Sang et al, 2013). In the clinical setting, HSP90 inhibitors
have been evaluated in multiple phase I and II clinical studies as
single agent and in combination with chemotherapy, hormonal
therapy or targeted agents (Goldman et al, 2013; Johnson et al, 2013;
Sessa et al, 2013; Socinski et al, 2013). Promising clinical activity has
been observed in patients with ALK-translocated crizotinib-resistant
NSCLC and in those with acquired EGFR T790M mutations, which
confer resistance to EGFR tyrosine kinase inhibitors (Johnson et al,
2013; Socinski et al, 2013).
Heat-shock protein 990 is an orally bioavailable synthetic small
molecule, which inhibits HSP90 via an ATP-binding site, resulting
in the degradation of ubiquitin proteasome pathway-driven client
proteins and inhibition of multiple oncoproteins. Its antitumour
effects have been demonstrated in preclinical models of different
malignancies that are dependent on HSP90 client proteins
(Lamottke et al, 2012; Menezes et al, 2012; Stuhmer et al, 2012;
Fu et al, 2013; Zitzmann et al, 2013). In this first-in-human, open-
label, phase I dose-escalation study, HSP990 was administered as a
single agent orally in two different dosing schedules of once weekly
and two times weekly. The primary objective of this study was to
establish the maximum-tolerated dose (MTD) and recommended
phase II dose (RP2D) of HSP990 in patients with advanced solid
malignancies based on these schedules. Secondary objectives
included the assessment of safety, tolerability and preliminary
efficacy, as well as the evaluation of the pharmacokinetic (PK)
profile and the PK–pharmacodynamic (PD) relationship of HSP990.
PATIENTS AND METHODS
Heat-shock protein 990 (Novartis, Basel, Switzerland) was
administered orally either once a week or two times a week on a
28-day cycle schedule. Regulatory and independent ethics
committee approvals were obtained in all participating sites of
this multicentre study. The National Cancer Institute Common
Toxicity Criteria for Adverse Events (NCI CTCAE) version 3.0
were used to evaluate toxicity.
Patient selection. Eligible patients were those with histologically
confirmed, advanced malignant solid tumours whose disease had
either progressed on standard therapy or for whom no standard
therapy was available. Inclusion criteria included: age 18 years or
older; World Health Organisation performance status (WHO PS)
of 0–2; at least one measurable lesion as defined by Response
Evaluation Criteria in Solid Tumours (RECIST) version 1.0;
documented disease progression before study entry, predicted life
expectancy of at least 12 weeks; ability to swallow capsules;
adequate haematopoietic, hepatic, and renal function and normal
electrolytes. Exclusion criteria included: pregnant or lactating
women; another primary malignancy; presence or history of
central nervous system metastases; acute or chronic hepatic or
renal disease; gastrointestinal impairment that may affect absorp-
tion of oral medications; significant cardiac comorbidities; HIV
infection; other severe or uncontrolled medical conditions; prior
treatment with HSP90 or histone deacetylase inhibitors; poor or
intermediate CYP2C9 metabolisers based on genotyping per-
formed at screening (homozygous for the CYP2C9*2 allele, or
either heterozygous or homozygous for the CYP2C9*3 allele);
concomitant use of CYP2C9 inhibitors; active therapeutic doses of
sodium warfarin or acenocumarol; and unresolved side effects
(Xgrade 2) from previous treatments. Patients required a washout
period of at least 4 weeks from prior systemic anticancer treatment
and radiation and 2 weeks from prior major surgery before starting
study drug.
Study design and dosing. The study design comprised a dose-
escalation part followed by a dose expansion cohort. In the dose-
escalation part, a minimum of three patients per cohort were
enrolled, although two patients without any treatment-related
adverse events (AEs 4grade 1 were sufficient for dose-escalation
decision. An adaptive Bayesian Logistic Regression Model (BLRM)
guided by the Escalation with Overdose Control principle was used
in the dose-escalation part (Rogatko et al, 2007). The BLRM with
overdose control was used to model the relationship between dose
and the probability of a patient experiencing a dose-limiting
toxicity (Babb et al, 1998). The dose-escalation part initially
planned to only include a once-weekly dose regimen of HSP990
starting from 2.5mg given orally, derived based on preclinical
studies. Owing to the potential for dropout during the first cycle of
treatment, cohort expansion was allowed provided enrolment
occurred within 14 days of treatment start of the third patient in
the same cohort. If either of the two patients in the cohort
experienced a DLT before the enrolment of the third patient, the
model was to be re-evaluated before enrolment of any additional
patients to that cohort. The dose expansion part of the once-weekly
schedule was performed at the MTD. To assess whether the
frequency and severity of neurologic toxicities could be attenuated
by splitting HSP990 dosing as a twice-weekly regimen, this
alternative schedule was introduced after expansion of the once-
weekly dose regimen. No dose expansion was conducted for the
twice-weekly dose regimen due to slow accrual and early
termination of the study. Intrapatient dose escalation was
permitted only after the first four cycles of treatment utilising
the same dosing schedule patients were initially assigned. A DLT
was defined as any clinically relevant AE or abnormal laboratory
values occurring within the first 28 days of HSP990 treatment as
specified in Supplementary Table 1. The MTD/RP2D was defined
based on recommendations of the Bayesian model, plus other
available safety and tolerability information. All investigators
reviewed safety data collected at each dose level before selection of
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the next dose level. At the completion of dose escalation, all
reviewers evaluated safety and DLT data, as well as recommenda-
tions by the Bayesian model, to select the MTD/RP2D.
HSP990 formulation and administration. Heat-shock protein
990 was administered orally once or two times weekly on a flat
dosing scale and treatment cycles were of 28 days duration. Heat-
shock protein 990 was supplied as 1, 2.5, 20 and 50mg hard gelatin
capsules. Fasting conditions were required (study drug was taken
30min after a light breakfast, followed by a 3-h fasting period). The
twice-weekly dosing schedule required at least 72 h between the two
doses, with both doses taken within a 7-day period. Administration
of HSP990 was allowed until disease progression, unacceptable
toxicity, investigator’s decision or patient withdrawal of consent.
Safety and efficacy assessments. Safety assessments consisted of
physical examination including neurological examination, vital
signs, weight, performance status assessment and documentation
of AEs and serious AEs (SAEs). In addition, laboratory investiga-
tions such as haematology, coagulation, biochemistry, urinalysis
and pregnancy test, if applicable, were conducted at baseline, on
day 1 of every treatment cycle, on the last visit and at any time
when clinically indicated. Electrocardiograms were performed on
day 1 of each cycle and multiple times on specific days throughout
the study treatment. Cardiac evaluations by ECHO or MUGA
scans were performed at baseline, at the end of cycles 2–4 and
every other month thereafter until the end of study or when
clinically indicated. Imaging with fluorodeoxyglucose positron
emission tomography (FDG-PET) was performed at baseline, on
day 10 of cycle 1 and on day 2 of cycle 3. Tumour assessments
based on radiological evaluations occurred at baseline, the end of
every two cycles and the end of treatment. Response assessment
was performed according to RECIST version 1.0.
PK assessments. Pharmacokinetic samples of HSP990 were
obtained and evaluated in all patients at all dose levels to
characterise the disposition of HSP990 and its metabolite(s) (when
appropriate) after oral administration of HSP990. Whole blood
samples (2.0ml) were obtained via venipuncture into an ethylene
diamine tetraacetic acid containing tube. Immediately after each
sample collection, the blood tubes were centrifuged to separate out
plasma. The plasma samples from all patients were assayed
centrally for HSP990 concentrations using a validated liquid
chromatography-tandem mass spectrometry assay.
Blood samples were collected at prescheduled timepoints after
the oral doses on days 1 and 22 of cycle 1 and on day 1 of cycle 2.
Owing to the food effect noted in dogs, a record of the meal and
related timing to HSP990 drug dosing was required. Non-
compartmental analysis using WinNonlin Pro (version 5.2;
Pharsight, Mountain View, CA, USA) was performed to calculate
the relevant PK parameters.
PD assessments. As HSP70 may be a novel biomarker to assess
the pharmacological effects of HSP90 inhibitors (Dakappagari et al,
2010), pre- and posttreatment peripheral blood mononuclear cell
(PBMC) samples were analysed to compare the levels of HSP70
measured by ELISA (Enzo Life Sciences, Farmingdale, NY, USA;
cat. no. ADI-EKS-700B). One 8ml sample of blood was collected at
pre- and posttreatment time points on days 1, 2, 3, 4 and 22 of
cycle 1 and on days 1, 2 and 3 of cycle 2.
Exploratory functional imaging. Exploratory efficacy assessment
was performed in all patients enrolled in the study utilising FDG-
PET to explore antitumour response by analysing changes in FDG
avidity. Scans were performed at screening on day 10 of cycle 1and
on day 2 of cycle 3. A reduction in maximum standardised uptake
value (SUV) summed across all target lesions (sSUVmax) ofX25%
was considered evidence of objective metabolic response. An
increase in sSUVmax of X25% was considered evidence of
progression. Any appearance of new PET lesions was categorised
as metabolic progression regardless of changes observed in target
lesion SUV assessment.
Statistical methods. Data analysis was performed using SAS
version 9.3 (Cary, NC, USA), with the exception of the BLRM,
which was performed using R version 2.8.1 and WinBUGS version
1.4.1. Data were summarised for demographic and baseline
characteristics, safety and efficacy measurements, and all relevant
PK and PD evaluations using descriptive statistics. For PK data, an
analysis of covariance was performed on log-transformed AUC
and Cmax (day 1 of cycle 1 and day 22 of cycle 1) using a linear
mixed-effect model to assess day effect. Summary statistics for
HSP70 induction in PBMCs were tabulated. Estimation of the
MTD in the dose-escalation part of the study was based on
the estimation of the probability of DLT in cycle 1 for patients in
the dose-determining set. For the once-weekly regimen, a BLRM
was used to model the dose–toxicity relationship and to compute
the posterior probability of a DLT at each dose level.
RESULTS
Patient characteristics. A total of 64 patients from three
investigational sites were enrolled in this study. Sixty-three patients
(98%) were eligible for dose-determining set given that one patient,
because of progression of disease, did not receive X75% of dose
without a DLT and 50 patients were evaluable for the biomarker
analysis subset. Fifty-four patients (84%) discontinued treatment
for disease progression, nine (14%) for AEs of any causality, of
which 78% (7 out of 9 patients) were considered drug-related, and
one patient (2%) withdrew consent. As summarised in Table 1,
Table 1. Patient population: all treated patients (N¼64)
Characteristics N (%)
Gender
Female 36 (56)
Male 28 (44)
Median age: years (range) 56.5 (25–75)
Cancer types
Colorectal 28 (44)
GI (non-colorectal) 10 (16)
Breast 9 (14)
Skin melanoma 5 (8)
Head/neck 2 (3)
Lung 1 (2)
Othersa 8 (12)
Baseline WHO PS
0 29 (45)
1 34 (53)
2 1 (2)
Prior antineoplastic therapy
Yes 64 (100)
No 0
Therapy type at last treatment
Chemotherapy 41 (64)
Hormone therapy 1 (2)
Targeted therapy 24 (53)
Othera 4 (6)
Number of prior treatments
1–2 11 (17)
3–4 32 (50)
44 21 (33)
Abbreviations: GI¼gastrointestinal; GIST¼gastrointestinal stromal tumour; WHO PS¼
World Health Organisation performance status.
aOthers include: ovary, kidney, sarcoma, thyroid, uveal melanoma and GIST.
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colorectal cancer was the most common tumour type (45%),
followed by non-colorectal gastrointestinal malignancies (16%) and
breast cancer (14%). All patients previously received systemic
treatments, with the majority of them (83%) having received three
or more lines of therapy. Nearly all (98%) patients had WHO PS 0
or 1 at baseline.
Dose escalation and MTD. During the dose-escalation part for
the once-weekly schedule, seven dose levels ranging from 2.5 to
60mg were evaluated. A total of seven patients experienced DLTs.
At 60mg once weekly, two patients experienced DLTs (40%). One
patient developed grade 1 decreased appetite, dysdiadochokinesia,
fatigue, hyperreflexia and tremor. Of note, this patient experienced
drug-related AEs that caused an inability to administer 75% of the
planned dose of HSP990, even though the reported events were not
in the grade range defined as a DLT. The second patient
experienced drug-related grade 3 tremor without any confounding
factor. In one patient, the dose of HSP990 was reduced, whereas
the other patient discontinued the study treatment. The MTD in
this study was declared as 50mg administered once weekly;
therefore, 16 additional patients were recruited at this dose in the
expansion phase. Of the 22 patients who received HSP990 at 50mg
once a week, 5 DLTs were encountered in 4 patients (grade 3
bilateral myoclonic hand movement, grade 3 diarrhoea, grade 3
prolonged QTc seen in 2 patients and grade 4 ALT and AST
increase), with diarrhoea and QTc prolongation occurring in the
same patient. The frequency of DLT at the 50mg once-weekly dose
level was 18% (4 out of 22 patients).
Dose escalation for the twice-weekly dose regimen started with
25mg two times a week and enrolled 11 patients. One of them
experienced DLT in the form of grade 1 extremity tremors,
superior limb extrapyramidal hypertropia and dysmetria; grade 2
ataxia, confusion and visual hallucination. Further dose escalation
beyond 25mg two times a week was not pursued, the study
stopped due to high interpatient PK variability and the lack of an
efficacy trend across all dose groups. Table 2 provides a summary
of the occurrences of DLT by dose level.
Safety. The most frequent drug-related AEs on this study were:
diarrhoea in 47 patients (73%), asthenia in 26 patients (41%),
anorexia in 16 patients (25%), insomnia in 16 patients (25%),
nausea in 14 patients (22%), dizziness in 12 patients (19%), tremor
in 12 patients (19%), abdominal pain in 10 patients (16%) and
vomiting in 9 patients (14%).
Study drug-related grade 3 or 4 AEs occurred in 15 patients
(23%). Grade 3 AEs were: diarrhoea (13%), increased ALT and/or
AST, asthenia, QTc prolongation and hyponatremia, each
occurring in two patients (3%). Grade 4 ALT and AST elevations
were each experienced in one patient in the 50mg weekly group.
Adverse events requiring dose adjustment or study drug interrup-
tion were reported in 19 patients (30%). Out of six deaths reported
on study and up to 28 days after the last dose, none of them were
considered treatment-related. At least one SAE was experienced in
26 patients (41%). Heat-shock protein 990-related SAEs were:
grade 1, ataxia, dizziness and tremor; grade 2, confusional state and
visual hallucination; grade 3, gastrointestinal disorder, myoclonic
hand movements and QTc prolongation; and grade 4, AST/ALT
elevation. Neurotoxicities leading to study drug discontinuation,
during and beyond cycle 1, were reported in nine patients (14%)
who presented with tremor, cerebellar syndrome, ataxia, extra-
pyramidal disorder, hyperreflexia, presyncope and syncope. Seven
patients (11%) overall reported a drug-related AE that led to study
discontinuation as shown in Table 2. No drug-related deaths
occurred in this study. All drug-related toxicities occurring in at
least 5% of all patients are summarised in Table 3 and grade 3 and
4 AEs suspected to be study drug related are reported in Table 4.
Treatment exposure, dose delay and dose modifications. The
median treatment duration for all patients was 8.0 weeks (range
Table 2. Dose-limiting toxicities, grade 3 toxicities beyond cycle 1 and other reasons for treatment discontinuation
Dose
level
Dose of
HSP990
(mg)
Total no.
of DLT
evaluable
patients
Total no.
of patients
with DLTs Description of DLT
Grade X3
drug-
related
AEs
beyond
cycle 1
Description of
grade X3 drug-
related AEs beyond
cycle 1
Total no. of
patients who
discontinue
HSP990 (cause)
beyond cycle 1
Once weekly
1 2.5 3 0 NA 0 NA 0
2 5 5 0 NA 0 NA 0
3 10 7 0 NA 0 NA 0
4 20 6 0 NA 7 Abdominal pain,
cramping, bloating,
digestive disorder,
nausea, vomiting,
diarrhoea, fatigue
1 (digestive
disorder)
5 30 4 0 NA 0 NA 0
6 50 22 4 G3 bilateral myoclonic hand
movement
G3 diarrhoea, and prolonged QTc
G3 prolonged QTc
G4 ALT and AST
6 Fatigue, QT
prolongation,
presyncope, syncope,
ALT elevation
5 (fatigue, QT
prolongation,
presyncope,
syncope)
7 60 5 2 G1 decreased appetite,
dysdiadochokinesia, fatigue,
hyperreflexia and tremor leading to
inability to administer 75% of the
planned dose of HSP990
G3 tremor
3 Diarrhoea 2 (diarrhoea)
Twice weekly
1 25 11 1 G1 extremities tremors, superior limb
extrapyramidal hypertrophia, G2
ataxia, confusion and visual
hallucination
2 Diarrhoea 0
Abbreviations: ALT¼ alanine transaminase; AST¼ aspartate aminotransferase; DLT¼dose-limiting toxicity; G¼grade; HSP¼heat-shock protein; NA¼not applicable.
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1.0–116.0 weeks). The highest median treatment duration (12.0
weeks) was reported in the 25mg twice-weekly group. Forty-six
patients (72%) received up to 12 weeks of treatment, with six
patients (9%) receiving 12 to 16 weeks of treatment, and the
remaining 12 patients (19%) receiving 416 weeks of treatment.
The majority of patients (89%) had a relative dose intensity of 0.9
to o1.1, with an overall median relative dose intensity of 1.0.
Overall, dose reductions, observed primarily in the cohorts dosed
at X50mg weekly, occurred in six patients, with only one patient
requiring more than one dose reductions. Main reasons for dose
reduction were neurological toxicities, QTc prolongation and
diarrhoea. Dose delays, mostly due to AEs, were observed in 22
patients, with five patients (8%) requiring more than one dose
delays.
PK analysis. In both dosing schedules, HSP990 was well absorbed,
with time to peak concentrations achieved B3 h postdose and
then declined mono- or biexponentially with a t1/2 of B20 h
(Figures 1A and B). Similar absorption rates (Tmax) and
comparable PK profiles were observed on days 1 and 22 of cycle
1 and day 1 of cycle 2 after multiple oral doses in individual
patients, which suggested low intrapatient PK variability. At the 50
and 60mg dose levels, a distribution phase after the peak was
observed in the concentration–time profiles, indicating rapid oral
absorption. On day 1, Cmax values were 496 ngml
 1 in the 50mg
once-weekly and 270 ngml 1 in the 25mg twice-weekly schedules,
and 552 to 232 ngml 1 at steady states, respectively. From days
1 to 22, related AUClast values changed from 8408 ng.hml
 1 to
7959 ngml 1 in the 50mg once-weekly schedule and from 12 580
to 14 195 ng.hml 1 in the 25mg twice-weekly schedule. The dose
splitting from 50mg once weekly to 25mg twice weekly decreased
the Cmax by half, while the weekly AUC was increased. The
increase in AUC was generally dose proportional in the dose range
from 2.5 to 60mg following the weekly oral doses on days 1 or 22
of cycle 1. The Cmax values increased slightly greater than dose
proportionally in the dose range from 2.5 to 60mg. Intersubject
variability in Cmax and AUC differed at each dose level but the
differences were relatively large at higher doses. Apparent clearance
(B6.4 l h 1) and volume of distribution (B200 l) suggest that
HSP990 has low systemic clearance and a large tissue distribution.
Similar PK profiles were observed on days 1 and 22 of cycle 1,
indicating no drug accumulation after multiple- or twice-weekly
doses. The HSP990 PK parameters after the oral doses on day 1 of
cycle 1 are summarised in Table 5.
PD analysis. To assess the PD effects of HSP990, HSP70 analysis
in PBMCs was performed by ELISA on a total of 50 patients.
Supplementary Figure 1 shows the highest HSP70 changes by
treatment group. For once-weekly administration, at dose ranges
from 2.5 to 60mg, HSP70 induction tended to increase with dose
across the 5mg weekly to 30mg weekly dose groups. Dose groups
above 20mg appeared to plateau, indicating a saturation effect.
There were a wide range of HSP70 values at each dose level,
suggesting interpatient PD variability. For twice-weekly adminis-
tration at a dose of 25mg, the level of HSP990 induction achieved
was greater than that seen in once weekly 30mg to 60mg dose
levels, indicating no saturation effect in the limit of our clinical
findings in a small group of patients.
Response evaluation. No partial or complete responses were
observed. Twenty-five (39%) patients showed stable disease as best
overall response, with a trend (7 out of 11 patients, 64%) towards
higher rates of stable disease in the twice-weekly dosing schedule.
Seven (11%) patients demonstrated a prolonged stable disease (X6
months), of which 71% (5 out of 7) were seen in either 50 or 60mg
once-weekly or 25mg twice-weekly regimens.
FDG-PET imaging. An overall decrease in FDG-PET uptake was
observed in the higher dose levels (50mg weekly and 25mg twice-
weekly groups) compared with the lower dose levels (2.5–30mg
weekly groups) as shown in Supplementary Figure 2. No complete
Table 3. All grades AEs suspected to be study drug related occurring in at least 5% of all patients (safety cohort)
Weekly schedule
Twice-weekly
schedule
2.5mg
(N¼3)
5mg
(N¼5)
10mg
(N¼7)
20mg
(N¼6)
30mg
(N¼5)
50mg
(N¼22)
60mg
(N¼5)
25mg
(N¼11)
All pts
(N¼64)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Pts with Z1 drug-related AEs 1 (33) 3 (60) 4 (57) 6 (100) 5 (100) 22 (100) 5 (100) 11 (100) 57 (89)
Constitutional
Asthenia 0 2 (40) 2 (29) 2 (33) 2 (40) 11 (50) 3 (60) 4 (36) 26 (41)
Insomnia 0 0 0 0 1 (20) 9 (41) 2 (40) 4 (36) 16 (25)
Gastrointestinal
Diarrhoea 0 3 (60) 2 (29) 6 (100) 4 (80) 18 (82) 5 (100) 9 (82) 47 (73)
Nausea 0 0 0 3 (50) 1 (20) 6 (27) 2 (40) 2 (18) 14 (22)
Anorexia 1 (33) 0 2 (29) 1 (17) 1 (20) 7 (32) 2 (40) 2 (18) 16 (25)
Abdominal pain 0 0 0 4 (67) 1 (20) 3 (14) 1 (20) 1 (9) 10 (16)
Vomiting 0 1 (20) 0 1 (17) 0 5 (23) 2 (40) 0 9 (14)
Weight loss 0 0 1 (14) 0 0 2 (9) 1 (20) 0 4 (6)
Neurology
Dizziness 0 2 (40) 0 1 (17) 0 6 (27) 1 (20) 2 (18) 12 (19)
Tremor 0 0 0 0 0 6 (27) 3 (60) 3 (27) 12 (19)
Ataxia 0 0 0 0 0 3 (14) 0 3 (27) 6 (10)
Cerebellar syndrome 0 0 0 0 0 1 (4) 2 (40) 2 (18) 5 (8)
Balance disorder 0 0 0 0 0 3 (14) 1 (20) 0 4 (6)
Headache 0 0 0 1 (17) 0 2 (9) 0 1 (9) 4 (6)
Muscle spasms 0 0 0 0 1 (20) 2 (9) 1 (20) 0 4 (6)
Laboratory
ALT increase 0 0 0 1 (17) 0 2 (9) 1 (20) 1 (9) 5 (8)
AST increase 0 0 0 1 (17) 0 2 (9) 1 (20) 1 (9) 5 (8)
Abbreviations: AE¼ adverse events; ALT¼ alanine transaminase; AST¼ aspartate aminotransferase; pts¼patients.
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metabolic response was seen in any of the patients treated. A total
of 11 patients (17%) had aX25% reduction in sSUVmax of target
lesions from baseline. These 11 patients received HSP990 at 5mg
weekly (1 patient), 30mg weekly (1 patient), 50mg weekly (6
patients) and 25mg twice weekly (3 patients). A summary of
tumour response as per RECIST version 1.0 is summarised in
Supplementary Figure 3.
DISCUSSION
This first-in-human, multicentre, phase 1 study of HSP990
established the MTD/RP2D at 50mg once weekly. The twice-
weekly schedule was evaluated to determine if neurological
toxicities encountered at the higher dose levels in the once-weekly
schedule could be minimised by reducing the peak drug
concentrations without compromising drug AUC exposures.
However, the alternate schedule of twice-weekly dosing did not
conclusively show improved tolerability. Therefore, in light of
neurological toxicities that persisted despite schedule change, and
the substantial interpatient PK variability observed, this study was
terminated without reaching MTD in the twice-weekly schedule.
Neurological toxicities occurring during phase I studies often
limit the development of novel compounds despite evidence of
preliminary antitumour activity (Cavaliere and Schiff, 2006).
Diaz-Rubio et al (1994) reported severe unexpected central
nervous system (CNS) toxicities of the cytostatic agent mitonafide,
whose development was later abandoned despite evidence of
antitumour activity (Diaz-Rubio et al, 1994). More recently, both
central and peripheral neurological toxicities of the JAK2 inhibitor
XL019 led to early termination of the phase I study (Verstovsek
et al, 2014). For many agents, even with a broad spectrum of
activity, the presence of neurological events likely result in
suboptimal dose and inappropriate schedule recommendation,
therefore limiting potential activity. Pivotal examples are repre-
sented by interleukin-2 and interferon, where the severity of CNS
neurological toxicity events has been associated with higher doses
leading to the modification of treatment schedules in different
tumour types (Chiarion-Sileni et al, 2006; Alwan et al, 2013).
Heat-shock protein 990 was found to be highly distributed in
the brain tissues in the rat model. Preclinical toxicology studies are
relevant to determine a reasonable expectation of safety for all new
molecules. Evaluation of neurological toxicity caused by anticancer
agents is challenging in animal models and interspecies differences
can lead to false predictions of a drug’s neurological toxicity
profile. Preclinical pharmacology studies of HSP990 showed no
effects on CNS in rats, but tremors and ataxia in dogs were
observed at doses of X2mg kg 1 (Novartis, 2012). This finding
corroborates previous reports, which suggests that non-rodent
models might be more predictive of neurological toxicities in
humans (Olson et al, 2000), highlighting the role of non-rodent
large animal model toxicology studies to identify appropriately
potential drug-related non-haematologic toxicities.
Although the majority of AEs reported in this phase I study of
HSP990 were mild or moderate in intensity, temporary and
reversible in nature and consistent with those typically encoun-
tered by patients with advanced cancers, the occurrence of dose-
dependent neurological toxicities led to frequent treatment delays
Table 4. Grade 3 and 4 adverse events suspected to be study drug related (safety cohort)
Weekly schedule
Twice-weekly
schedule
2.5mg
(N¼3)
5mg
(N¼5)
10mg
(N¼7)
20mg
(N¼6)
30mg
(N¼5)
50mg
(N¼22)
60mg
(N¼5)
25mg
(N¼11)
All pts
(N¼64)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Constitutional
Asthenia 0 0 0 1 (17) 0 1 (4) 0 0 2 (3)
Insomnia 0 0 0 0 0 0 0 0 0
Gastrointestinal
Diarrhoea 0 0 0 1 (17) 0 2 (9) 2 (40) 3 (27) 8 (13)
Nausea 0 0 0 0 0 0 0 0 0
Anorexia 0 0 0 0 0 0 0 0 0
Abdominal pain 0 0 0 1 (17) 0 0 0 0 1 (2)
Vomiting 0 0 0 1 (17) 0 0 0 0 1 (2)
Weight loss 0 0 0 0 0 0 0 0 0
Dehydration 0 0 0 0 0 0 1 (20) 0 1 (2)
Neurology
Dizziness 0 0 0 0 0 0 0 0 0
Tremor 0 0 0 0 0 0 1 (20) 0 1 (2)
Ataxia 0 0 0 0 0 0 0 0 0
Cerebellar syndrome 0 0 0 0 0 0 0 0 0
Balance disorder 0 0 0 0 0 0 0 0 0
Headache 0 0 0 0 0 0 0 0 0
Muscle spasms 0 0 0 0 0 0 0 0 0
Myoclonus 0 0 0 0 0 1 (4) 0 0 1 (2)
Neurotoxicity 0 0 0 0 0 1 (4) 0 0 1 (2)
Presyncope 0 0 0 0 0 1 (4) 0 0 1 (2)
Syncope 0 0 0 0 0 1 (4) 0 0 1 (2)
Laboratory
ALT increase 0 0 0 0 0 2 (9) 0 0 2 (3)
AST increase 0 0 0 0 0 2 (9) 0 0 2 (3)
Hyponatremia 0 0 0 0 0 0 2 (40) 0 2 (3)
Cardiac
Prolonged QT interval 0 0 0 0 0 2 (9) 0 0 2 (3)
Abbreviations: ALT¼ alanine transaminase; AST¼ aspartate aminotransferase; pts¼patients.
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or drug discontinuation. The attempt to split the daily dose of
HSP990 into two to reduce peak drug concentrations did not
attenuate its neurological toxicity, suggesting that this event is
likely related to drug exposure. Previous findings have shown toxic
effects of HSP90 inhibitors on oligodendrocyte precursor cells,
with consequent reduction of oligodendrocyte population and
prevention of remyelination during HSP90 inhibitors therapy in
cell cultures (Alcazar and Cid, 2009). In addition, in vitro and
in vivo data have shown the dual ability of HSP90 inhibitors to
protect murine neural progenitor cells from their natural apoptosis
at low doses and increase their death at high doses (Wang et al,
2011). These findings may explain the neurological toxicities seen
in our study, particularly at higher dose levels of HSP990, and
reflect the toxicity profile seen with other molecules that belong to
the same class of agents (Dickson et al, 2013; Saif et al, 2014).
Despite several challenges, including the identification of potential
therapeutic targets and exploitable therapeutic index, lack of
predictive biomarker and occurrence of severe toxicities, the
development of HSP90 inhibitors has gained increasing interest in
the cancer field, given the molecular chaperones regulation on several
vital proteins. Phase II and III trials with AUY922 and ganetespib
(STA-9090) are ongoing in prostate, gastric, pancreatic, breast and
lung cancers. These agents have shown modest clinical benefit in
both monotherapy or combination with chemotherapy or targeted
agents, with the exception of NSCLC and triple-negative breast
cancer where activity appears promising (Awada et al, 2013; Johnson
et al, 2013; Ramalingam et al, 2013; Thota et al, 2014).
In contrast to the major classes of molecular chaperones, HSP90
uses repeated cycles of client protein binding, ATP hydrolysis as
well as interaction with cochaperones, such as HSP70, to stabilise
and activate B200 client proteins, several of which represent
oncoproteins such as HER2, EGFR, AKT and RAF kinase (Zhang
and Burrows, 2004; Chandarlapaty et al, 2010). Interesting
preclinical and clinical results have supported the role of these
agents in NSCLC, particularly in patients with tumours resistant to
ALK inhibitors or EGFR inhibitors. (Johnson et al, 2013; Sang et al,
2013; Socinski et al, 2013). In contrast to ganetespib and AUY922,
which are available in intravenous formulation only, our study
investigated HSP990 that has the advantage of oral availability
(Goldman et al, 2013; Sessa et al, 2013). Disappointingly in this
study, the narrow therapeutic index, interpatient PK variability and
neurological toxicities limited the development of HSP990.
The induction of HSP70 and HSP27 through the heat-shock
transcription factor 1 frequently occurs as a result of HSP90
inhibitor effect (Erlichman, 2009). In normal tissue, the increased
expression of these proteins leads to protection from some
toxicities related to HSP90 inhibition. The upregulation of these
molecular chaperones may also protect cancer cells, and thus may
potentially result in resistance to HSP90 blockade (Guo et al, 2005;
McCollum et al, 2006). Previous data have shown that silencing of
HSP70 and/or HSP27 markedly increases cancer cell sensitivity to
HSP90 inhibitors (McCollum et al, 2006; Powers et al, 2008). In
our study, the HSP70 was evaluated as a measure of target
inhibition in PBMCs. Heat-shock protein 70 induction range
appeared wide, increasing with HSP990 doses of up to 30mg once
weekly, but plateaued at higher dose levels, indicating a saturation
effect. Surrogate tissues such as PBMCs are not always reflective of
tumour effects, and in this case, while HSP70 induction may reflect
on-target HSP90 inhibition, this PD biomarker may actually
reflect the emergence of escape mechanisms in the tumour cells.
The evaluation of pharmacological inhibitors of HSP70 and HSP27
is under current development (Evans et al, 2010), and it would be
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Figure 1. Median concentration–time profiles for plasma HSP990 on
day 1 of cycle 1 (A) and day 22 of cycle 1 (B).
Table 5. Summary of PK parameters (mean±s.d.) of HSP990 following the oral doses on day 1 of cycle 1
Dose Cmax (ngml
1) Tmax (h) AUCinf (ng.hml
1) AUClast (ng.hml
1) T1/2 (h)
2.5mg weekly (N¼3) 12.9±4.3 2.98–3.05 394±77 309±31 25.6±17.1
5mg weekly (N¼ 5) 24.5±6.5 1.0–23.2 915±375 835±373 26.1±9.7
10mg weekly (N¼ 7) 70.3±29.9 3.0–8.03 1993±1073 1883±1049 19.0±4.6
20mg weekly (N¼ 6) 129±89 3.0–8.0 4027±2843 3667±2715 20.4±4.1
30mg weekly (N¼ 5) 253±83 3.0–4.0 6142±2428 5854±2358 16.8±1.0
50mg weekly (N¼ 22) 496±279 2.95–5.97 10 108±10229 8408±5569 20.2±10.9
60mg weekly (N¼ 5) 700±424 3.0–3.08 9712±4901 9405±4939 17.6±4.9
25mg twice weekly (N¼11) 270±125 1.0–75.8 NA 12 580±s 17.9±9.4
Abbreviations: AUC¼ area under the curve; NA¼ not applicable; PK¼pharmacokinetic.
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of interest to combine such drugs with HSP90 inhibitors to reduce
compensatory escapes.
Several trials have tested the role of FDG-PET as an important
early marker of efficacy in drug development (Kraeber-Bodere
et al, 2012; McArthur et al, 2012). In the current study, no
complete metabolic responses were seen, whereas 17% of patients
had partial metabolic responses, mostly at higher HSP990 dose
levels. The metabolic responses seen in this study did not correlate
with conventional objective tumour response. These results may
reflect the unclear role of FDG-PET as an indicator of drug-
induced modulation of tumour metabolism (O’Brien et al, 2012;
Piessen et al, 2013). In our study, no complete or partial responses
were observed, and stable disease as per RECIST was achieved in
39% of patients. Although not a primary end point in phase I
studies, preliminary efficacy data often influence go-no-go
decisions on the continued development of a new agent.
Substantial biases such as differences in tumour biology, tumour
measurement errors and timing of radiological assessments can
affect the reliability of disease stabilisation as a true measure of
antitumour activity (Le Tourneau et al, 2014). Despite the
development of alternative methods such as tumour growth rate
(Ferte et al, 2014), at present no consensus has been reached and
RECIST still remains the conventional approach to evaluate
tumour response in clinical trials.
Many molecularly targeted agents, which have successfully
attained regulatory approval, are linked to specific predictive
biomarkers that help identify sensitive or resistant patient
populations. However, this characteristic may not be applicable
to HSP90 inhibitors as their antitumour activity is mediated by
downstream effects via multiple pathways. Given the pleiotropic
spectrum of targets of this class of agents that may preclude the
utility of specific predictive biomarkers, a major challenge is the
identification of specific client proteins that may ultimately serve as
predictive or surrogate biomarkers for those cancers likely to
respond to HSP90 inhibitors. Nevertheless, many compounds such
as ipilimumab or bevacizumab are used as standard of care despite
the absence of predictive biomarkers (Hurwitz et al, 2004; Hodi
et al, 2010).
The relevant questions remain as to whether drugs such as
HSP90 inhibitors with their wide range of downstream targets can
exert sufficient antitumour activity to translate into clinical impact
in one or more malignancies, and whether their therapeutic indices
are dampened by off-target effects and compensatory mechanisms
that induce drug resistance. Based on the promising results in
NSCLC and the activity of HSP90 inhibitors on the EGFR pathway,
new studies have been developed to evaluate the combination of
EGFR and HSP90 inhibitors (Johnson et al, 2013). In addition,
given their effects on cell cycle arrest and their ability to enhance
DNA damage and apoptosis, combination studies with taxanes or
with radiotherapy (Sain et al, 2006; Milanovic et al, 2013) may be
of interest for further development of HSP90 inhibitors.
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